{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:01:11Z","timestamp":1790017271933,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Topical permethrin (5%), though considered the treatment of choice for scabies, has few drawbacks (expensive, poor compliance). This study aimed to compare the efficacy, safety, and cost-effectiveness of topical permethrin (5%) and oral ivermectin for treating childhood scabies. This randomized controlled trial was conducted in the dermatology and pediatric outpatient clinic of a tertiary care center between August 2023 and December 2024. Children in the study and control groups received oral ivermectin (200\u2009\u00b5g\/kg) and 5% permethrin, respectively, at an interval of 7\u2009days. The cure rate at the 4th week was the primary outcome. Secondary outcomes were cure rate (1st and 2nd week), lesion count per patient (1st, 2nd, and 4th weeks), microscopic clearance (1st, 2nd, and 4th weeks), treatment failure (4th week), adverse events, reinfestation at the 6-month follow-up period, and cost to successfully treat one case. Three hundred and fifty-five children were included in either group. Though a significantly higher proportion of children in the control group were cured at the 1st week (41.8% vs 62.9%, p-value &amp;lt;.001), the cure rate was similar between the groups at the 2nd and 4th weeks (P-value &amp;gt;.05). Treatment failure was also similar in both groups (5.1% vs 3.9%, P-value\u2009=\u2009.47). The cost to treat one case successfully in the study and control groups was \u20b944.2 ($0.46) and \u20b9140.4 ($1.47), respectively. Reinfestation during the follow-up period was similar in the two groups (P-value &amp;gt;.05). Oral ivermectin may be a cost-effective alternative treatment of childhood scabies. The trial was registered in the Clinical Trial Registry of India (Registration no.: CTRI\/2023\/07\/055910, dated 31 July 2023).<\/jats:p>","DOI":"10.1093\/tropej\/fmag063","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:08:40Z","timestamp":1788520120000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of topical 5% permethrin and oral ivermectin for treatment of childhood scabies: a randomized controlled trial"],"prefix":"10.1093","volume":"72","author":[{"given":"Nazima","family":"Khatun","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, NRS Medical College , Kolkata, 700014,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayani","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Burdwan Medical College , Burdwan, 713104,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamirul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Burdwan Medical College , Burdwan, 713104,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-5845","authenticated-orcid":false,"given":"Sudipto","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Burdwan Medical College , Burdwan, 713104,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraknath","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Burdwan Medical College , Burdwan, 713104,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092114100784800_fmag063-B1","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMcp052784","article-title":"Clinical practices. Scabies","volume":"354","author":"Chosidow","year":"2006","journal-title":"N Engl J Med"},{"key":"2026092114100784800_fmag063-B2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.pcl.2009.09.002","article-title":"Skin disorders, including pyoderma, scabies, and tinea infections","volume":"56","author":"Andrews","year":"2009","journal-title":"Pediatr Clin North Am"},{"key":"2026092114100784800_fmag063-B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0065-308X(04)57005-7","article-title":"Scabies: new future for a neglected disease","volume":"57","author":"Walton","year":"2004","journal-title":"Adv Parasitol"},{"key":"2026092114100784800_fmag063-B4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S1473-3099(15)00132-2","article-title":"Prevalence of scabies and impetigo worldwide: a systematic review","volume":"15","author":"Romani","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026092114100784800_fmag063-B5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/QCO.0b013e32835e085b","article-title":"Scabies: a suitable case for a global control initiative","volume":"26","author":"Hay","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2026092114100784800_fmag063-B6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(06)68772-2","article-title":"Scabies","volume":"367","author":"Heukelbach","year":"2006","journal-title":"Lancet"},{"key":"2026092114100784800_fmag063-B7","doi-asserted-by":"publisher","first-page":"1297337","DOI":"10.3389\/fcimb.2023.1297337","article-title":"Resistance and pseudo-resistance to permethrin: the importance of controlling scabies","volume":"13","author":"Rinaldi","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2026092114100784800_fmag063-B8","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1111\/jdv.17339","article-title":"Is scabies becoming less sensitive to permethrin therapy?","volume":"35","author":"Mazzatenta","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092114100784800_fmag063-B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3122\/jabfm.2017.01.160190","article-title":"Epidemiology, diagnosis, and treatment of scabies in a dermatology office","volume":"30","author":"Anderson","year":"2017","journal-title":"J Am Board Fam Med"},{"key":"2026092114100784800_fmag063-B10","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.lanwpc.2024.101144","article-title":"Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trial","volume":"49","author":"Gwee","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026092114100784800_fmag063-B11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/jdv.14351","article-title":"European guideline for the management of scabies","volume":"31","author":"Salavastru","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092114100784800_fmag063-B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.48882","article-title":"Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies","volume":"41","author":"Bachewar","year":"2009","journal-title":"Indian J Pharmacol"},{"key":"2026092114100784800_fmag063-B13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4103\/0378-6323.84063","article-title":"Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study","volume":"77","author":"Sharma","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026092114100784800_fmag063-B14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4103\/0378-6323.100571","article-title":"Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies","volume":"78","author":"Chhaiya","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026092114100784800_fmag063-B15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0190-9622(00)90131-2","article-title":"A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies","volume":"42","author":"Usha","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2026092114100784800_fmag063-B16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjd.18943","article-title":"The 2020 International Alliance for the Control of Scabies consensus criteria for the diagnosis of scabies","volume":"183","author":"Engelman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026092114100784800_fmag063-B17","first-page":"51","article-title":"How to calculate sample size in randomized controlled trial?","volume":"1","author":"Zhong","year":"2009","journal-title":"J Thorac Dis"},{"key":"2026092114100784800_fmag063-B18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.47203\/IJCH.2019.v31i01.025","article-title":"Modified BG Prasad socioeconomic classification, update-2019","volume":"31","author":"Pandey","year":"2019","journal-title":"Indian J Comm Health"},{"key":"2026092114100784800_fmag063-B19","doi-asserted-by":"publisher","first-page":"adv00112","DOI":"10.2340\/00015555-3468","article-title":"The management of scabies in the 21st century: past, advances and potentials","volume":"100","author":"Bernigaud","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026092114100784800_fmag063-B20","first-page":"189","article-title":"The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies","volume":"59","author":"Ranjkesh","year":"2013","journal-title":"Ann Parasitol"},{"key":"2026092114100784800_fmag063-B21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/09546634.2016.1151855","article-title":"Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies","volume":"27","author":"Abdel-Raheem","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"2026092114100784800_fmag063-B22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1346-8138.2011.01481.x","article-title":"Treatment of scabies: comparison of permethrin 5% versus ivermectin","volume":"39","author":"Goldust","year":"2012","journal-title":"J Dermatol"},{"key":"2026092114100784800_fmag063-B23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev.ento.44.1.429","article-title":"The insect voltage-gated sodium channel as target of insecticides","volume":"44","author":"Zlotkin","year":"1999","journal-title":"Annu Rev Entomol"},{"key":"2026092114100784800_fmag063-B24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","article-title":"Ivermectin 20 years on: maturation of a wonder drug","volume":"21","author":"Geary","year":"2005","journal-title":"Trends Parasitol"},{"key":"2026092114100784800_fmag063-B25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMct0910329","article-title":"Permethrin and ivermectin for scabies","volume":"362","author":"Currie","year":"2010","journal-title":"N Engl J Med"},{"key":"2026092114100784800_fmag063-B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1523-1747.ep12532792","article-title":"Age-related changes in sebaceous gland activity","volume":"73","author":"Pochi","year":"1979","journal-title":"J Invest Dermatol"},{"key":"2026092114100784800_fmag063-B27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archderm.1990.01670260037006","article-title":"Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies","volume":"126","author":"Schultz","year":"1990","journal-title":"Arch Dermatol"},{"key":"2026092114100784800_fmag063-B28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/archderm.135.6.651","article-title":"Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies","volume":"135","author":"Chouela","year":"1999","journal-title":"Arch Dermatol"},{"key":"2026092114100784800_fmag063-B29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.18369","article-title":"Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study","volume":"182","author":"Levy","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/72\/5\/fmag063\/71292064\/fmag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/72\/5\/fmag063\/71292064\/fmag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:10:16Z","timestamp":1790014216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/doi\/10.1093\/tropej\/fmag063\/8825283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmag063","relation":{},"ISSN":["0142-6338","1465-3664"],"issn-type":[{"value":"0142-6338","type":"print"},{"value":"1465-3664","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,20]]},"article-number":"fmag063"}}